Pasireotide

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 750 publications

Recurrent Cushing's disease due to postoperative seeding of tumor cells in the sphenoid sinus: a case report with review of the literature.

Recurrent Cushing's disease due to postoperative seeding of tumor cells in the sphenoid sinus: a case report with review of the literature.

Journal: Endocrine journal

Published: June 10, 2026

Beyond the catalytic site: Voxilaprevir and Pasireotide as repurposed therapeutics for conformational inhibition of ADAR1.

Beyond the catalytic site: Voxilaprevir and Pasireotide as repurposed therapeutics for conformational inhibition of ADAR1.

Journal: Journal of molecular graphics & modelling

Published: May 16, 2026

Can acromegaly be controlled in all cases?

Can acromegaly be controlled in all cases?

Journal: Journal of neuroendocrinology

Published: May 08, 2026

Current Insights into Pasireotide Therapy for Uncontrolled Acromegaly: Biochemical Response, Tumor Reduction, and Glycemic Safety in a Real-World Latin American Cohort.

Current Insights into Pasireotide Therapy for Uncontrolled Acromegaly: Biochemical Response, Tumor Reduction, and Glycemic Safety in a Real-World Latin American Cohort.

Journal: Life (Basel, Switzerland)

Published: May 06, 2026

Management and safety of somatostatin receptor ligands and pegvisomant in pregnant women with acromegaly: a narrative review of the literature.

Management and safety of somatostatin receptor ligands and pegvisomant in pregnant women with acromegaly: a narrative review of the literature.

Journal: Endocrine

Published: May 04, 2026

Ex Vivo drug sensitivity in patient-derived 3D cultures in acromegaly and its association with clinical predictors.

Ex Vivo drug sensitivity in patient-derived 3D cultures in acromegaly and its association with clinical predictors.

Journal: Pituitary

Published: April 19, 2026

Somatostatin and Its Analogues as Second-Line Treatments in Non-Neoplastic Conditions.

Somatostatin and Its Analogues as Second-Line Treatments in Non-Neoplastic Conditions.

Journal: International journal of molecular sciences

Published: March 31, 2026

Resistant prolactinomas.

Resistant prolactinomas.

Journal: Best practice & research. Clinical endocrinology & metabolism

Published: March 28, 2026

Pasireotide induces proteins related to autophagy in cancer cells.

Pasireotide induces proteins related to autophagy in cancer cells.

Journal: Endocrine

Published: March 25, 2026

Comparative Efficacy and Safety of Octreotide, Lanreotide, and Pasireotide in ADPKD and PLD: A Network Meta-analysis with Real-world Evidence from the FAERS Database.

Comparative Efficacy and Safety of Octreotide, Lanreotide, and Pasireotide in ADPKD and PLD: A Network Meta-analysis with Real-world Evidence from the FAERS Database.

Journal: Clinical and translational gastroenterology

Published: March 12, 2026

Safety and Efficacy of Once-Daily Oral Paltusotine in Acromegaly: ACROBAT Advance Open-Label Extension Up to 4 Years.

Safety and Efficacy of Once-Daily Oral Paltusotine in Acromegaly: ACROBAT Advance Open-Label Extension Up to 4 Years.

Journal: The Journal of clinical endocrinology and metabolism

Published: March 03, 2026

Adenoma receptors and histologic characteristics determining management outcomes.

Adenoma receptors and histologic characteristics determining management outcomes.

Journal: The Journal of clinical endocrinology and metabolism

Published: February 06, 2026

Showing 1-12 of 750

Last Updated: 09/26/2026